Oppenheimer analyst Jay Olson raised his price target for Neurocrine to $140 form $128 based on a series of recent events including clinical data for Ingrezza and opicapone, top-line Phase 3 results for elagolix and setback for a competitor in uterine fibroids. The analyst views all of these as de-risking events for Neurocrine and is especially encouraged by recent long-term data for Ingrezza showing sustained clinical response, high levels of patient satisfaction and a treatment withdrawal study suggesting chronic therapy benefits patients on Ingrezza. Olson reiterates an Outperform rating on the shares.